Carfilzomib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1674 publications

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Journal: Future oncology (London, England)

Published: April 13, 2026

Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma

Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma

Journal: Zhongguo shi yan xue ye xue za zhi

Published: March 18, 2026

Bortezomib Induces Apoptosis via Upregulation of Abhd4 in Peripheral Nerve Cells.

Bortezomib Induces Apoptosis via Upregulation of Abhd4 in Peripheral Nerve Cells.

Journal: Biological & pharmaceutical bulletin

Published: March 15, 2026

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Journal: Cancers

Published: February 25, 2026

Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors.

Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors.

Journal: Molecular pharmaceutics

Published: February 17, 2026

Mesoporous polydopamine-based biomimetic nanoplatform for immunotherapy of multiple myeloma by homologous targeting and systemic immune activation.

Mesoporous polydopamine-based biomimetic nanoplatform for immunotherapy of multiple myeloma by homologous targeting and systemic immune activation.

Journal: Biomaterials advances

Published: February 05, 2026

Multiple myeloma associated with secondary plasma cell leukemia, gastric mucosal extramedullary plasmacytic infiltration, and concurrent moderately differentiated papillary adenocarcinoma: a case report.

Multiple myeloma associated with secondary plasma cell leukemia, gastric mucosal extramedullary plasmacytic infiltration, and concurrent moderately differentiated papillary adenocarcinoma: a case report.

Journal: Frontiers in oncology

Published: January 22, 2026

Contemporary approach to desensitization: Targeted therapies for HLA sensitized pediatric heart transplant candidates - Study design and rationale.

Contemporary approach to desensitization: Targeted therapies for HLA sensitized pediatric heart transplant candidates - Study design and rationale.

Journal: JHLT open

Published: January 15, 2026

Structure-Based Design of Pan-Selective Peptide Epoxyketones for the Three Human Immunoproteasome Active Sites.

Structure-Based Design of Pan-Selective Peptide Epoxyketones for the Three Human Immunoproteasome Active Sites.

Journal: Journal of medicinal chemistry

Published: January 08, 2026

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 06, 2026

Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.

Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.

Journal: Cancers

Published: January 03, 2026

The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND8.

The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND8.

Journal: Experimental hematology & oncology

Published: January 03, 2026

Showing 1-12 of 1,674

Last Updated: 04/28/2026